FDA Inspection Intelligence Hub

From Readiness to Confidence to Compliance

Two comprehensive FDA inspection resources - a verified regulatory Do's & Don'ts guide and a step-by-step operational Playbook - built exclusively from FDA's own regulatory language.

balance

Regulatory Reference Guide

Do's & Don'ts Guide

Verified FDA regulatory language mapped to severity levels - Critical, Major, Minor, and IBP - across all three inspection roles: management, QC unit, and production & lab personnel.

Open Guide

assignment

Step-by-Step Field Guide

Inspection Playbook

A practical, 8-step operational guide for first-time and every-time inspected facilities from pre-inspection preparation through post-inspection CAPA management and continuous readiness.

Open Playbook

What's Inside Each Resource

Both documents are complementary - the Do's & Don'ts provides the regulatory what and why, the Playbook provides the operational how.

Do's & Don'ts Guide

· FDA Terminology Corrections - what the FDA actually says vs. consulting jargon

· Section 1: Firm Management & Quality Unit Representatives

o Entry procedures · Credential verification · Inspection scope confirmation
o Communication protocols · Record requests · Verbal commitments policy
o Closing meeting conduct · FDA 483 receipt and response timeline

· Section 2: Quality Control Unit - Document Review & Data Integrity

o ALCOA principles in practice - full regulatory citation mapping
o Audit trail requirements · Electronic records · OOS investigation rules

· Section 3: Production & Laboratory Personnel

o Equipment status labeling · Facility conduct · Gowning requirements
o Contemporaneous documentation · Chromatographic data retention

Inspection Playbook

· Step 1: Pre-inspection preparation

Team Roles, Command Room, Documents, Mock Inspection

· Step 2: Arrival protocol

First 5 minutes, Credential Verification, Form FDA 482

· Step 3: Opening meeting

Setup, Team Activation, 7 Golden Rules

· Step 4: During inspection

Document Handling, Facility Tour, Employee interviews. Daily Routine: Morning Brief · Real-Time Tracking · Evening debrief

· Step 5: Closing meeting

Form FDA 483 Receipt, Signing Protocol

· Step 6: Written 483 response

4 Principles, What to Avoid, Timelines

· Step 7: FDA classification

NAI · VAI · OAI · Warning Letter Protocol

· Step 8: 90-day post-inspection readiness cycle

Continuous Improvement and Sustainable Compliance

Quick Print Checklist

All phases in a single reference sheet

Why It Matters

Built on FDA's Actual Words

Most inspection guides use terms that don't appear anywhere in FDA regulatory documents. This resource corrects that - every DO and DON'T is directly cited to its regulatory source.

Verified Regulatory Language Only

Every instruction is grounded in IOM 2025, 21 CFR 210/211/Part 11, or FDA guidance documents. Consulting-only terms are explicitly labeled as IBP (Industry Best Practice) with no FDA source.

Severity-Classified Guidance

Every Do and Don't is tagged Critical, Major, Minor, or IBP - so you know exactly what constitutes a potential CGMP violation vs. a best practice recommendation.

March 2026 FDA Draft Guidance Incorporated

The newest FDA draft guidance on responding to Form FDA 483 observations (Docket FDA-2025-D-1504, March 9, 2026) is fully integrated - including the 15-business day response requirement and CAPA commitment policy.